Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.51 |
| ▸ | MC5R | P33032 | 6/20 | 0.51 |
| ▸ | MC3R | P41968 | 6/20 | 0.51 |
| ▸ | MC1R | Q01726 | 6/20 | 0.51 |
| ▸ | CTSG | P08311 | 2/20 | 0.51 |
| ▸ | TSLP | Q969D9 | 9/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881404 | 1.00 | MC4R (0.51) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL12146083 | 0.92 | TSLP (0.56) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL13038593 | 0.84 | ITGB3 (0.53) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL13881412 | 0.83 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL13319649 | 0.82 | CTSG (0.69) | CTSGTSLPPLAU | |
| SCHEMBL14274987 | 0.81 | CHRNA10 (0.55) | MC4RMC5RMC3RMC1RTSLP | |
| SCHEMBL13351721 | 0.81 | CTSG (0.62) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL18767059 | 0.80 | CACNA1B (0.58) | TSLP | |
| SCHEMBL13881402 | 0.79 | ITGB3 (0.54) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL19605458 | 0.79 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | MUC1, MSN, SNX9 | MC4R 1436/4885MC5R 2419/4885MC3R 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.